Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · IEX Real-Time Price · USD
37.98
+0.03 (0.08%)
At close: Jul 19, 2024, 4:00 PM
37.53
-0.45 (-1.18%)
Pre-market: Jul 22, 2024, 5:47 AM EDT
Apellis Pharmaceuticals Employees
Apellis Pharmaceuticals had 702 employees as of December 31, 2023. The number of employees decreased by 65 or -8.47% compared to the previous year.
Employees
702
Change (1Y)
-65
Growth (1Y)
-8.47%
Revenue / Employee
$746,538
Profits / Employee
-$594,406
Market Cap
4.61B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 702 | -65 | -8.47% |
Dec 31, 2022 | 767 | 291 | 61.13% |
Dec 31, 2021 | 476 | 102 | 27.27% |
Dec 31, 2020 | 374 | 139 | 59.15% |
Dec 31, 2019 | 235 | 148 | 170.11% |
Feb 26, 2019 | 87 | 48 | 123.08% |
Feb 28, 2018 | 39 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Select Medical Holdings | 54,600 |
PACS Group | 32,433 |
Integer Holdings | 10,500 |
RadNet | 7,872 |
Haemonetics | 3,657 |
Inspire Medical Systems | 1,011 |
TransMedics Group | 584 |
BridgeBio Pharma | 550 |
APLS News
- 3 days ago - Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm - PRNewsWire
- 3 days ago - Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results - GlobeNewsWire
- 12 days ago - Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - GlobeNewsWire
- 23 days ago - Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU - GlobeNewsWire
- 6 weeks ago - Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference - GlobeNewsWire